Compare Divis Laboratories with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PANACEA BIOTECH - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PANACEA BIOTECH DIVIS LABORATORIES/
PANACEA BIOTECH
 
P/E (TTM) x 32.6 12.2 266.7% View Chart
P/BV x 7.4 2.9 250.3% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 DIVIS LABORATORIES   PANACEA BIOTECH
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
PANACEA BIOTECH
Mar-18
DIVIS LABORATORIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,142364 313.7%   
Low Rs533129 412.9%   
Sales per share (Unadj.) Rs146.696.8 151.5%  
Earnings per share (Unadj.) Rs33.0-12.4 -266.2%  
Cash flow per share (Unadj.) Rs38.4-2.9 -1,346.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs222.850.4 442.1%  
Shares outstanding (eoy) m265.4761.25 433.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.72.5 224.3%   
Avg P/E ratio x25.3-19.9 -127.6%  
P/CF ratio (eoy) x21.8-86.4 -25.2%  
Price / Book Value ratio x3.84.9 76.8%  
Dividend payout %30.30-   
Avg Mkt Cap Rs m222,31815,101 1,472.2%   
No. of employees `00010.82.5 436.1%   
Total wages/salary Rs m4,5611,516 300.9%   
Avg. sales/employee Rs Th3,616.02,401.9 150.5%   
Avg. wages/employee Rs Th423.8614.2 69.0%   
Avg. net profit/employee Rs Th814.9-307.9 -264.6%   
INCOME DATA
Net Sales Rs m38,9155,928 656.5%  
Other income Rs m1,13482 1,378.4%   
Total revenues Rs m40,0496,010 666.4%   
Gross profit Rs m12,617845 1,492.6%  
Depreciation Rs m1,425585 243.4%   
Interest Rs m131,006 1.3%   
Profit before tax Rs m12,313-664 -1,855.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,54399 3,593.5%   
Profit after tax Rs m8,770-760 -1,154.0%  
Gross profit margin %32.414.3 227.4%  
Effective tax rate %28.8-14.9 -193.6%   
Net profit margin %22.5-12.8 -175.8%  
BALANCE SHEET DATA
Current assets Rs m45,3515,603 809.3%   
Current liabilities Rs m6,5076,910 94.2%   
Net working cap to sales %99.8-22.0 -452.8%  
Current ratio x7.00.8 859.5%  
Inventory Days Days127206 61.6%  
Debtors Days Days9584 113.6%  
Net fixed assets Rs m21,1609,941 212.9%   
Share capital Rs m53161 866.1%   
"Free" reserves Rs m58,6253,026 1,937.6%   
Net worth Rs m59,1563,087 1,916.3%   
Long term debt Rs m05,707 0.0%   
Total assets Rs m67,83216,076 422.0%  
Interest coverage x926.80.3 272,330.6%   
Debt to equity ratio x01.8 0.0%  
Sales to assets ratio x0.60.4 155.6%   
Return on assets %12.91.5 846.9%  
Return on equity %14.8-24.6 -60.2%  
Return on capital %20.83.9 532.1%  
Exports to sales %024.0 0.0%   
Imports to sales %21.817.5 124.3%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs m8,4851,040 816.0%   
Fx inflow Rs m32,3591,600 2,022.4%   
Fx outflow Rs m9,0421,131 799.2%   
Net fx Rs m23,317469 4,975.9%   
CASH FLOW
From Operations Rs m7,7591,180 657.4%  
From Investments Rs m-4,783553 -865.1%  
From Financial Activity Rs m-3,142-1,644 191.2%  
Net Cashflow Rs m-16690 -185.1%  

Share Holding

Indian Promoters % 52.0 74.5 69.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.6 1,966.7%  
FIIs % 19.0 1.3 1,461.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 23.6 72.9%  
Shareholders   31,796 10,259 309.9%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ALEMBIC PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON   

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - GSK PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS